OraSure Technologies (OSUR) Osake Kurssi
OraSure Technologies Kurssi
Liikevaihto on kasvanut 2,8 % vuodessa viimeisten 19 vuoden aikana 115,02 M USD:een. Osakekohtainen tulos on kasvanut 11,4 % vuodessa viimeisten 17 vuoden aikana. OraSure Technologiesn nettomarginaali on nyt −59,8 %, laskenut −9,8 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 4,00 USD, eli yli nykyhintaa 3,0 %. 6 analyytikosta 0 suosittaa ostoa — kokonaiskonsensus on Myy.
OraSure Technologies osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
OraSure Technologies liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset OraSure Technologies -osakkeesta
OraSure Technologies Inc. operates under a diversified business model. The company specializes in the development, manufacturing, and distribution of point-of-care diagnostic and specimen collection devices. OraSure's products serve various industries, including healthcare, criminal justice, drug treatment, and public health. With a focus on innovative technologies, OraSure delivers solutions for rapid diagnostic testing, such as HIV and hepatitis C detection. The company also offers oral fluid collection devices for DNA testing and substance abuse monitoring. Through its comprehensive business model, OraSure Technologies Inc. remains committed to enhancing healthcare outcomes and improving overall testing processes.
OraSure Technologies Inc is primarily active in the biotechnology and healthcare industries.
The main competitors of OraSure Technologies Inc in the market are Abbott Laboratories, Quidel Corporation, and Hologic, Inc.
OraSure Technologies Inc. is a leading global provider of diagnostic testing and specimen collection devices. Founded in 1987, the company has a rich history of developing innovative solutions for infectious diseases and substance abuse testing. OraSure Technologies Inc. is focused on improving public health by offering non-invasive testing options that are accurate, reliable, and user-friendly. With a diverse portfolio of products, including the OraQuick® In-Home HIV Test and the OraCollect™ DNA Device, the company aims to empower individuals and healthcare professionals with effective tools for early detection and prevention. OraSure Technologies Inc. continues to drive advancements in diagnostics, making a significant impact on the healthcare industry.
OraSure Technologies Inc has achieved several significant milestones. One of the notable achievements is the development and FDA approval of the OraQuick® In-Home HIV Test, which is the first rapid HIV test that can be used by individuals in the comfort of their own homes. This groundbreaking product has helped to increase HIV testing rates and improve early detection. Additionally, OraSure Technologies Inc has made significant strides in the field of oral fluid diagnostics, paving the way for advancements in drug testing and healthcare diagnostics. The company continues to innovate and collaborate with industry partners, solidifying its position as a leader in the diagnostic testing space.
OraSure Technologies Inc is primarily present in the United States.
OraSure Technologies Inc represents core values of innovation, integrity, and excellence. With a strong corporate philosophy, the company strives to make a positive impact on healthcare by developing and providing innovative diagnostic tests and specimen collection devices. OraSure Technologies Inc is dedicated to improving public health outcomes through its commitment to quality, accuracy, and reliability. Through cutting-edge technologies and a focus on customer satisfaction, the company has become a leader in the industry, delivering accurate and rapid diagnostic solutions. OraSure Technologies Inc's dedication to constant innovation and maintaining the highest standards makes it a trusted name in the healthcare sector.
Analyytikot asettavat tällä hetkellä OraSure Technologies-osakkeelle keskimääräisen tavoitehinnan 4,00 USD (mediaani: 4,00 USD), mikä merkitsee +3,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 6 analyytikkoarvioon.
6 analyytikkoa arvioi tällä hetkellä OraSure Technologies-osaketta: 0 suosittaa ostoa, 3 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat OraSure Technologies-yhtiöltä 122,11 M USD liikevaihtoa ja −0,66 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla OraSure Technologies-osake noteerataan hintaan 3,46 EUR (3,88 USD).
OraSure Technologies-osake (OSUR) on listattuna 4 pörssissä, muun muassa: NASDAQ (OSUR), SIX (Zürich) (EP3.SW), Frankfurt (EP3.F), München (EP3.MU).
OraSure Technologies Inc is a US company specializing in the development and marketing of diagnostic tests, devices, and medical accessories. It was founded in 2000 as a spin-off of Epitope Inc. Currently, OraSure Technologies Inc employs over 500 employees and is headquartered in Bethlehem, Pennsylvania. The company's business model is based on various divisions focusing on different medical applications. These include divisions such as "Infectious Diseases," "Clinical Laboratory Diagnostics," and "Molecular Diagnostics." In the Infectious Diseases division, OraSure Technologies Inc offers various tests for detecting infections, including the OraQuick® HCV Rapid Antibody Test, a test for the rapid and easy detection of Hepatitis C antibodies in the blood. The company also manufactures the OraQuick® HIV Self-Test and the OraQuick® In-Home HIV Test, which provide a simple and convenient way for patients to test themselves for HIV. The Clinical Laboratory Diagnostics division focuses on the development of diagnostic tests for use in clinical laboratories. OraSure Technologies Inc offers products such as the Intercept® i2F Body Fluid Collection Device and the Intercept® Oral Fluid Drug Test, which enable fast and reliable analysis of various body fluids. The Molecular Diagnostics division focuses on the development of molecular biological tests for detecting diseases based on DNA and RNA analysis. The company offers products such as the OraSure® OMNIgene® GUT Kit for stabilizing DNA samples and the OraQuick® Ebola Rapid Antigen Test, which allows for rapid and reliable detection of Ebola antigens. In addition to the development and marketing of diagnostic tests and devices, OraSure Technologies Inc also offers medical diagnostic accessories. These include the Intercept® Collection Kit and the OraSure® Sample Collection Device, which enable reliable and secure sample collection for blood tests and other examinations. OraSure Technologies Inc's business model is based on a strong focus on research and development of new products, as well as the safe and reliable production of diagnostic tests and devices for use in medical facilities. Through close collaboration with leading medical research institutes and universities, OraSure Technologies Inc is able to develop innovative and groundbreaking products for medical diagnostics, making an important contribution to healthcare and disease prevention.
odotettu liikevaihto OraSure Technologies on 122,11 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto OraSure Technologies on −47,34 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
OraSure Technologies:n hinta-voitto-suhde (P/E) on tällä hetkellä −5,87. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan OraSure Technologies-osakkeen arvostusta.
OraSure Technologies:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,28. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii OraSure Technologies-osakkeen arvostuskennuslukuna.
OraSure Technologies:n Eulpool-laatuscore on 1/10.
OraSure Technologies:n ISIN on US68554V1089. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
OraSure Technologies:n WKN on 881351. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
OraSure Technologies:n ticker on OSUR. Tämä pörssinoteeraus käytetään OraSure Technologies-osakkeiden kauppaan pörssissä.
OraSure Technologies osake
OraSure Technologies vertaisryhmä
OraSure Technologies Ticker
OraSure Technologies FIGI
Kaikki tunnusluvut ja syvällinen analyysi OraSure Technologies:sta
Meidän osakeanalyysimme OraSure Technologies-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut OraSure Technologies:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: